Literature DB >> 34045814

Acute Peripheral Arterial Thrombosis in COVID-19 Patients on Therapeutic Anticoagulation.

Abhyuday Kumar1, Neeraj Kumar2, Shettru K Arun1, Subhajit Subhajit1, Arunima Pattanayak1.   

Abstract

Coronavirus disease-2019 (COVID-19) disease is often complicated by venous thrombosis and embolism. However, arterial thrombosis in a patient already on therapeutic anticoagulation is a rare occurrence. In one patient, we found thrombosis of the radial artery leading to ischemia of the fingers and lateral part of the palm. In another patient, thrombosis was found in the anterior tibial artery, resulting in ischemia of the limb and amputation. Both these patients were on a therapeutic dose of low-molecular-weight heparin. In both cases, heparin infusion was started but with little benefit. It is suggested that intensified anticoagulation should be done in patients at high-risk venous thrombosis, and prompt interventional thrombectomy should be done in cases of failure of pharmacological anticoagulation. HOW TO CITE THIS ARTICLE: Kumar A, Kumar N, Arun SK, Ghosh S, Pattanayak A. Acute Peripheral Arterial Thrombosis in COVID-19 Patients on Therapeutic Anticoagulation. Indian J Crit Care Med 2021;25(4):461-462.
Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.

Entities:  

Keywords:  Artery; COVID-19; Intensive care; Low-molecular-weight heparin; Thrombosis

Year:  2021        PMID: 34045814      PMCID: PMC8138647          DOI: 10.5005/jp-journals-10071-23793

Source DB:  PubMed          Journal:  Indian J Crit Care Med        ISSN: 0972-5229


Introduction

Coronavirus disease-2019 (COVID-19) disease is often complicated by venous thrombosis and embolism. In a recent meta-analysis, the incidence of venous thromboembolism was found to be 26%; pulmonary embolism with or without deep vein thrombosis (DVT) occurred in 12% of patients and DVT alone in 14%.[1] However, data on arterial thrombosis in COVID-19 patients are limited. Here, we describe two cases admitted to the intensive care unit (ICU) who developed acute peripheral arterial thrombosis despite on therapeutic anticoagulation leading to limb-threatening ischemia.

Case Descriptions

Case 1

A 66-year-old male COVID-19 patient with a history of diabetes and hypertension was admitted to the ICU with complaints of increased respiratory distress. He was put on invasive mechanical ventilation and was paralyzed because of severe acute respiratory distress syndrome requiring high oxygen concentration. He was started on antibiotics, hydroxychloroquine, dexamethasone, therapeutic dose of low-molecular-weight heparin (LMWH), and other supporting treatments. Both the left and right radial arteries were used for arterial blood gas analysis in due course of his stay in ICU. On day 3 of ICU admission, an arterial cannula was inserted in the right radial artery because of septic shock. On day 4, a red dusky discoloration was noticed on the tip of the left thumb, index, and little fingers. On Doppler ultrasonography (USG), the left ulnar artery was found to be patent, whereas the left radial artery was found to be thrombosed. The patient was started on an infusion of unfractionated heparin and aspirin. Overnight the tip of the index and little fingers turned to be red dusky to blackish, while the whole of left thumb was dark red (Fig. 1). Digital subtraction angiography (DSA) and thrombectomy were not performed due to clinical deterioration of the patient, and the patient died on day 6 due to sepsis and respiratory failure.
Fig. 1

Ischemic changes seen on the volar surface of palm and fingers

Case 2

A 75-year-old male COVID-19 patient with a history of hypertension and chronic obstructive pulmonary disease was shifted to the ICU on the fourth day of admission to the hospital because of respiratory distress and was put on noninvasive ventilation. The patient was started on inj.remdesivir, dexamethasone, antibiotics, and therapeutic dose of LMWH, along with mechanical compression devices and other supportive management. On day 14, the patient started complaining of pain in the right lower limb with discoloration of the dorsum of the foot. Doppler USG was performed, which showed right lower limb microthrombi occluding branches of the anterior tibial artery. The patient was started on unfractionated heparin, aspirin, and ticagrelor. However, the color of the distal part of the foot along with fingers started turning reddish black in due course (Fig. 2). The patient underwent right lower limb thrombectomy by DSA with balloon angioplasty on the 20th day of hospitalization. However, there was complete ischemia of the distal part of the foot with loss of sensation. The patient was weaned off the ventilator after 15 days and discharged with a plan of amputation after a clear line of demarcation is developed. Below the ankle, amputation of the dead necrotic tissues was done after 1 month of the discharge.
Fig. 2

Sequence of ischemic changes seen on dorsum and volar surfaces of the foot

Ischemic changes seen on the volar surface of palm and fingers Sequence of ischemic changes seen on dorsum and volar surfaces of the foot

Discussion

SARS-CoV-2 generates an imbalanced proinflammatory status (cytokine storm) with endothelial inflammation that can lead to venous or arterial thrombosis.[2] SARS-CoV-2 directly attacks vascular endothelial cells and activates the coagulation cascade after causing endothelial injury. This results in cytokine storm activating the widespread coagulation factors while inhibiting the fibrinolysis causing extensive thrombosis similar to disseminated intravascular coagulation. Interleukin-6 (IL-6) is a key factor in SARS-CoV-2-induced inflammatory storm. While IL-6 can stimulate the liver to synthesize fibrinogen and thrombopoietin, it also upregulates the expression of vascular endothelial growth factor to disrupt the stability of the vascular barrier and stimulate monocytes to express more tissue factors, thereby activating the extrinsic pathway of coagulation.[3] D-dimer, platelet count, C-reactive protein, and erythrocyte sedimentation rate elevations have been found to be predictive of thrombotic complications.[4] In our cases, D-dimer was found to be increased out of proportion in comparison with other inflammatory markers (Table 1). Prophylactic anticoagulation has been proved to be useful for venous thromboembolism; however, it is unclear whether prophylactic or full anticoagulation will be beneficial for arterial thrombosis caused by COVID-19.[5] Our clinical scenario was unique in describing the development of acute limb ischemia due to arterial thrombosis despite being on full therapeutic anticoagulation with LMWH. A formal investigation is warranted with a focus on arterial thrombotic complications to characterize the arterial consequences of COVID-19. Intensified anticoagulation should be done in patients with high venous thrombotic risk. Prompt interventional thrombectomy is also needed in cases of failure of pharmacological anticoagulation.
Table 1

Inflammatory markers on the day of clinical suspicion of thrombosis

Inflammatory markersCase 1Case 2
Platelet count1.4 lac/cumm0.9 lac/cumm
C-reactive protein20.6 mg/L86 mg/L
D-dimer>20 μg/mL12.25 μg/mL
Lactate dehydrogenase2114 U/L515 U/L
Serum ferritin782 ng/mL362 ng/mL
Interleukin-6110 pg/mL60 pg/mL
Inflammatory markers on the day of clinical suspicion of thrombosis
  4 in total

1.  Acute peripheral arterial thrombosis in COVID-19. Role of endothelial inflammation.

Authors:  E Gonzalez Cañas; A Gimenez Gaibar; L Rodriguez Lorenzo; J G Castro Rios; A Martinez Toiran; M R Bella Cueto; B Bella Burgos; M Espasa Soley
Journal:  Br J Surg       Date:  2020-08-05       Impact factor: 6.939

2.  COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection.

Authors:  Hanny Al-Samkari; Rebecca S Karp Leaf; Walter H Dzik; Jonathan C T Carlson; Annemarie E Fogerty; Anem Waheed; Katayoon Goodarzi; Pavan K Bendapudi; Larissa Bornikova; Shruti Gupta; David E Leaf; David J Kuter; Rachel P Rosovsky
Journal:  Blood       Date:  2020-07-23       Impact factor: 25.476

3.  Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis.

Authors:  Angelo Porfidia; Emanuele Valeriani; Roberto Pola; Ettore Porreca; Anne W S Rutjes; Marcello Di Nisio
Journal:  Thromb Res       Date:  2020-08-12       Impact factor: 3.944

4.  COVID-19 and its implications for thrombosis and anticoagulation.

Authors:  Jean M Connors; Jerrold H Levy
Journal:  Blood       Date:  2020-06-04       Impact factor: 25.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.